Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.99 - $1.8 $38,115 - $69,300
-38,500 Reduced 78.41%
10,600 $11,000
Q2 2024

Aug 15, 2024

SELL
$1.58 - $2.51 $38,078 - $60,490
-24,100 Reduced 32.92%
49,100 $84,000
Q1 2024

May 07, 2024

SELL
$2.02 - $3.14 $138,370 - $215,090
-68,500 Reduced 48.34%
73,200 $174,000
Q4 2023

Feb 14, 2024

SELL
$1.59 - $3.85 $113,208 - $274,120
-71,200 Reduced 33.44%
141,700 $471,000
Q3 2023

Nov 14, 2023

BUY
$3.74 - $5.45 $507,518 - $739,565
135,700 Added 175.78%
212,900 $796,000
Q2 2023

Aug 11, 2023

BUY
$3.79 - $8.3 $292,588 - $640,760
77,200 New
77,200 $329,000
Q4 2022

Feb 14, 2023

BUY
$5.69 - $10.07 $244,670 - $433,010
43,000 New
43,000 $340,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $116M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.